Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Nuwellis Inc (NUWE)

Nuwellis Inc (NUWE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,364
  • Shares Outstanding, K 516
  • Annual Sales, $ 8,860 K
  • Annual Income, $ -20,210 K
  • 60-Month Beta 0.44
  • Price/Sales 0.25
  • Price/Cash Flow N/A
  • Price/Book 0.99
Trade NUWE with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/24
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -127.62
  • Growth Rate Est. (year over year) +882.79%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.34 +35.26%
on 07/10/24
8.23 -45.07%
on 06/25/24
-1.96 (-30.23%)
since 06/17/24
3-Month
3.34 +35.26%
on 07/10/24
14.00 -67.73%
on 04/25/24
-5.21 (-53.54%)
since 04/17/24
52-Week
3.34 +35.26%
on 07/10/24
98.35 -95.41%
on 07/26/23
-77.03 (-94.46%)
since 07/17/23

Most Recent Stories

More News
Global Rheumatoid Arthritis Drugs Market Expected To Hit US$ 70 Billion By 2030

/PRNewswire/ -- According to the Centers for Disease Control and Prevention, arthritis affects approximately one in every four Americans, or 58.5 million...

SILO : 2.08 (-12.97%)
BXRX : 0.0218 (+7.39%)
HOTH : 0.9726 (+4.58%)
KALA : 7.51 (-3.96%)
NUWE : 4.52 (-1.36%)
Nuwellis (NASDAQ: NUWE) Reports Clinical Data Showing 100% Survival Rate Using Ultrafiltration in High-Risk CABG Patients

Nuwellis, Inc. (NASDAQ: NUWE) is engaged as a medical device company, which is focused on the development and commercialization of

NUWE : 4.52 (-1.36%)
Nuwellis, Inc. Announces Second Quarter 2022 Financial Results

MINNEAPOLIS, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE) announced today its results for the second quarter ended June 30, 2022,...

NUWE : 4.52 (-1.36%)
Nuwellis Announces the Submission of the AVOID-HF Clinical Analysis as a Late Breaking Clinical Trial at HFSA

The Finkelstein-Schoenfeld Method of Win Ratios Analysis Provides New Insights Into Superiority of Ultrafiltration over Diuretics in Treating Fluid...

NUWE : 4.52 (-1.36%)
Nuwellis, Inc. To Announce Second Quarter 2022 Financial Results on August 9, 2022

MINNEAPOLIS, July 14, 2022 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ: NUWE) announced today that its second quarter 2022 financial results will be...

NUWE : 4.52 (-1.36%)
Nuwellis Initiates Its Outpatient Heart Failure Strategy Using Aquadex Ultrafiltration Therapy

MINNEAPOLIS, July 12, 2022 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a commercial-stage company focused on improving the quality of life for...

NUWE : 4.52 (-1.36%)
Nuwellis Announces First Patient Enrolled in its Pivotal Trial REVERSE-HF

REVERSE-HF will evaluate ultrafiltration therapy in comparison to IV diuretics to treat heart failure patients with fluid overload...

NUWE : 4.52 (-1.36%)
Nuwellis Expands Pediatric Access to Ultrafiltration Therapy at Hospitals in Florida and Arkansas

Pediatric Segment Growth Continues at 36% CAGR...

NUWE : 4.52 (-1.36%)
Nuwellis, Inc. Announces Adjournment of Annual Meeting of Stockholders Due to Lack of Quorum

MINNEAPOLIS, May 17, 2022 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ: NUWE), today announced that the Company’s 2022 Annual Meeting of Stockholders, on...

NUWE : 4.52 (-1.36%)

Business Summary

Nuwellis Inc. is a medical device company. It is focused on developing, manufacturing and commercializing the Aquadex SmartFlow(R) System for ultrafiltration therapy. Nuwellis Inc., formerly known as CHF Solutions, is headquartered in Minneapolis, Minn.

See More

Key Turning Points

3rd Resistance Point 5.32
2nd Resistance Point 5.01
1st Resistance Point 4.79
Last Price 4.52
1st Support Level 4.26
2nd Support Level 3.95
3rd Support Level 3.73

See More

52-Week High 98.35
Fibonacci 61.8% 62.06
Fibonacci 50% 50.85
Fibonacci 38.2% 39.63
Last Price 4.52
52-Week Low 3.34

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar